Related Experiment Videos

Therapeutic targets for heart failure: beyond beta-adrenergic and renin-angiotensin system blockade

Kousaku Iwatsubo1, Yoshihiro Ishikawa

  • 1Cardiovascular Research Institute, Department of Cell Biology, New Jersey Medical School-UMDNJ, Newark, NJ 07103, USA.

Recent Patents on Cardiovascular Drug Discovery
|January 29, 2008
PubMed

Insights

Heart failure remains a significant health issue. This review explores new molecular targets, including beta adrenergic and renin-angiotensin systems, for improved heart failure treatment.

Area of Science:

  • Cardiology
  • Molecular Biology
  • Pharmacology

Background:

  • Heart failure is a leading cause of death globally.
  • Current pharmacological therapies show limited success in reducing heart failure morbidity and mortality.
  • Emerging research indicates novel molecular targets for heart failure treatment.

Purpose of the Study:

  • To review the mechanisms underlying the beneficial effects of targeting specific molecular pathways in heart failure.
  • To identify potential new therapeutic strategies for heart failure management.
  • To discuss relevant patents concerning these molecular targets.

Main Methods:

  • Literature review of recent studies on heart failure molecular targets.
  • Analysis of the role of beta adrenergic receptor signaling pathway molecules.
  • Investigation of molecules within the renin-angiotensin system and calcium signaling pathways.

Main Results:

  • Key molecules in the beta adrenergic receptor signaling pathway are implicated in heart failure progression.
  • Transgenic mouse studies demonstrate beneficial effects of modulating these molecules.
  • The renin-angiotensin system and calcium signaling pathways present additional therapeutic targets.

Conclusions:

  • Modulating specific molecular targets offers promising avenues for heart failure treatment.
  • Further research into these pathways could lead to more effective therapies.
  • Patented strategies highlight the clinical interest in these molecular targets for heart failure.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.